Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carsten Utoft Niemann

Showing results (1-10 of 91) with videos related to

Pageof 10
Sort By:
Blood|August 24, 2023
BTK inhibitors: safety + efficacy = outcomeCarsten Utoft Niemann
Ugeskrift for Laeger|October 29, 2014
[Targeted treatment of chronic lymphocytic leukaemia]Carsten Utoft Niemann
Blood Advances|January 30, 2026
TP53-aberrated CLL: is BTK inhibitor monotherapy enough?Carsten Utoft Niemann
Ugeskrift for Laeger|October 28, 2015
[Washington DC vs. Copenhagen]Carsten Utoft Niemann
Blood|October 22, 2020
Cost-effectiveness targeting CLLCarsten Utoft Niemann
Blood|May 4, 2023
Immediate COVID-19 treatment in CLLCarsten Utoft Niemann
Leukemia Research|February 14, 2026
Clinical trial evidence + real world data: How do we ensure equal access to optimal CLL careMoritz Fürstenau, Carsten Utoft Niemann
Haematologica|July 5, 2018
Immune failure, infection and survival in chronic lymphocytic leukemia in DenmarkMichael Asger Andersen, Carsten Utoft Niemann
Leukemia & Lymphoma|October 6, 2021
Artificial intelligence models in chronic lymphocytic leukemia - recommendations toward state-of-the-artRudi Agius, Mehdi Parviz, Carsten Utoft Niemann
Drugs|November 4, 2018
Targeting Bruton's Tyrosine Kinase Across B-Cell MalignanciesCaspar da Cunha-Bang, Carsten Utoft Niemann
Pageof 10

Showing results (1-10 of 91) with videos related to

Sort By:
Pageof 10
Blood|August 24, 2023
BTK inhibitors: safety + efficacy = outcomeCarsten Utoft Niemann
Ugeskrift for Laeger|October 29, 2014
[Targeted treatment of chronic lymphocytic leukaemia]Carsten Utoft Niemann
Blood Advances|January 30, 2026
TP53-aberrated CLL: is BTK inhibitor monotherapy enough?Carsten Utoft Niemann
Ugeskrift for Laeger|October 28, 2015
[Washington DC vs. Copenhagen]Carsten Utoft Niemann
Blood|October 22, 2020
Cost-effectiveness targeting CLLCarsten Utoft Niemann
Blood|May 4, 2023
Immediate COVID-19 treatment in CLLCarsten Utoft Niemann
Leukemia Research|February 14, 2026
Clinical trial evidence + real world data: How do we ensure equal access to optimal CLL careMoritz Fürstenau, Carsten Utoft Niemann
Haematologica|July 5, 2018
Immune failure, infection and survival in chronic lymphocytic leukemia in DenmarkMichael Asger Andersen, Carsten Utoft Niemann
Leukemia & Lymphoma|October 6, 2021
Artificial intelligence models in chronic lymphocytic leukemia - recommendations toward state-of-the-artRudi Agius, Mehdi Parviz, Carsten Utoft Niemann
Drugs|November 4, 2018
Targeting Bruton's Tyrosine Kinase Across B-Cell MalignanciesCaspar da Cunha-Bang, Carsten Utoft Niemann
Pageof 10